Indicated for: breast cancer
Route of administration: injectable
Substance: fulvestrant (antineoplastic agent)
ATC: L02BA03 (Antineoplastic and immunomodulating agents | Hormone antagonists and related agents | Anti-estrogens)
Fulvestrant is a medication used to treat advanced breast cancer in postmenopausal women, especially when the disease is hormone-sensitive. It works by blocking estrogen receptors on cancer cells, thereby preventing their growth and multiplication.
Fulvestrant is administered by intramuscular injection, usually once a month, under medical supervision. The dose and treatment schedule are determined by your doctor based on the stage of the disease and response to therapy. It is important to follow the treatment regularly to achieve the best results.
Side effects may include pain at the injection site, fatigue, nausea, bone or joint pain, and hot flashes. In rare cases, allergic reactions or changes in liver function may occur. Any unusual symptoms should be reported to your doctor immediately.
Fulvestrant is an effective option for controlling advanced breast cancer, but it requires careful medical monitoring. Follow your doctor's instructions and do not stop treatment without their approval to ensure the therapy's effectiveness and safety.